

O I P E J C 1 0
 DEC 04 2002
 PATENT & TRADEMARK
 TOTAL A

TOTAL AMOUNT OF PAYMENT

(\$) 130.00

Attorney Docket No. 509582000211

~~DEC 20 2002~~

METHOD OF PAYMENT

FEE CALCULATION (continued)

- ☐
- Check
- ☐
- Credit Card
- ☐
- Money Order
- ☐
- Other

FEE CALCULATION

1. BASIC FILING FEE

SUBTOTAL (1) **(\\$)**

2. EXTRA CLAIM FEES

		Extra Claims		Fee from below	Fee Paid
Total Claims	- 20** =	.	x	=	\$
Independent Claims	- 3** =	.	x	=	\$
Multiple Dependent				=	\$

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claims, if not paid
109	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)*

** or number previously paid, if greater; For reissues, see above.

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
1253/2253	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
1401/2401	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design Issue fee	
144	620	244	310	Plant Issue fee	
122	130	122	130	Petitions of the Commissioner	130.00
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per properties (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional Invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)	(\$) 130.00
---------------------	--------------------

SUBMITTED BY

Name (Print/Type)	Wayne C. Jaeschke, Jr.
-------------------	------------------------

Registration No.
(Attorney/Agent)

(regno) 38,503

Complete (if applicable)

Telephone (703) 760-7756


Signature

Date _____

December 4, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 2.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



RECEIVED

DEC 20 2002


TECHNOLOGY CENTER R3700

Attorney Docket: 509582000211 Date: December 17, 2001
Inventor(s): David H. MCDANIEL USSN: 09/819,083
Title: PROCESS FOR TREATMENT OF PSORIASIS

Papers enclosed: 1. Transmittal for Missing Parts of Application
2. Copy of Decision Granting Petition
3. Combined Declaration and Power of Attorney
4.
5.

Attorney Docket: 509582000211 Date: December 17, 2001
Inventor(s): David H. MCDANIEL USSN: 09/819,083
Title: PROCESS FOR TREATMENT OF PSORIASIS

Papers enclosed: 1. Transmittal for Missing Parts of Application
2. Copy of Decision Granting Petition
3. Combined Declaration and Power of Attorney
4.
5.



RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prepared by: WCI/bck

2/07

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on December 4, 2002.


Debbie Labriny

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David H. McDaniel

Serial No.: 09/819,083

Filing Date: February 15, 2001

For: PROCESS FOR TREATMENT OF
PSORIASIS

Examiner: UNASSIGNED

Group Art Unit: UNASSIGNED

PETITION FOR ACTION ON THE MERITSCommissioner for Patents
Washington, D.C. 20231

Sir:

This application was filed on February 15, 2002. The most recent official communication received was a decision granting applicant's petition to have this application examined as a divisional of prior application 09/203,178, dated October 15, 2001. In accordance with the requirements of the decision on applicant's petition, a combined declaration and power of attorney was filed on December 17, 2002. No communication has been received from the Office since that time.

On November 18, 2002, applicant's representatives contacted the Office and were informed by Ms. Eugenia Jones, of the Petitions Branch of the Office, that this file could not be located after a diligent search. Included, therefore, is a true and accurate copy of applicant's file

12/05/2002 MGE BREW1 00000049 031952 09819083

01 FC:1460 130.00 CH

va-18682

for this application, so that the Office's file can be reconstructed and prosecution of this application can resume.


Applicant respectfully requests that the Commissioner grant applicant's request to reconstruct this file and immediately begin prosecution on the merits of this application.

Included herewith is payment of the petition fee required pursuant to 37 CFR 1.17(h). In the event that the transmittal letter is separated from this document and the Patent & Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952**, referencing 509582000211.


Respectfully submitted,

Dated: December 4, 2002

By:


Wayne C. Jaeschke, Jr.
Registration No. 38,503

Morrison & Foerster LLP
1650 Tysons Blvd., Suite 300
McLean, Virginia 22102
Telephone: (703) 760-7756
Facsimile: (703) 760-7777



Paper No. 3

ALEX CHARTOVE
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
1333 NEW HAMPSHIRE AVENUE, N.W., SUITE 400
WASHINGTON, DC 20036

COPY MAILED

OCT 15 2001

OFFICE OF PETITIONS

In re Application of
Dr. David H. McDaniel
Application No. 09/819,083
Filed: February 15, 2001
For: Process for Treatment of Psoriasis

:
: DECISION GRANTING
: PETITION
:
:

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

This is a decision on the petition filed June 4, 2001, requesting that a divisional Continued Prosecution Application (CPA) (identified in the petition by attorney docket No. 509582000211), deposited February 15, 2001, based on prior application No. 09/203,178 be treated as a divisional application under 37 CFR 1.53(b), rather than under 37 CFR 1.53(d), and be accorded a filing date of February 15, 2001.

The application papers filed February 15, 2001, and identified by attorney docket No. 071340.0019, requested treatment as a CONTINUED PROSECUTION APPLICATION (CPA) under 37 CFR 1.53(d) based on prior application No. 09/203,178. The petition filed June 4, 2001, states that the applicant mistakenly requested a filing under 37 CFR 1.53(d), but a filing under 37 CFR 1.53(b) was intended. Accordingly, the applicant requests that the application be treated as a divisional application under 37 CFR 1.53(b).

It is noted that the application papers filed February 15, 2001, included a complete specification and drawings. Therefore, the papers are presently complete for filing date purposes under 37 CFR 1.53(b). The application papers filed February 15, 2001, were filed while the prior application was still pending. The prior application No. 09/203,178 issued as U.S. Patent No. 6,283,956 on September 4, 2001.

Therefore, on petition, the application papers filed on February 15, 2001, will be treated as a divisional application filed under 37 CFR 1.53(b).

The petition is granted.

The 37 CFR 1.53(b) application has been assigned application No. 09/819,083.

DOCKETED
Cath / Declaration
12/15/01
5/15/02

A courtesy copy of this decision is being mailed to the address identified in the petition. However, it is noted that the correspondence address for the present application is contained in the application papers filed February 15, 2001. The Customer Number identified in the transmittal letter is not a valid Customer Number. No further communications will be mailed to the address provided in the petition unless a power of attorney/change of correspondence address is filed.

It is noted that an oath or declaration under 37 CFR 1.63 is missing. Applicant is given **TWO MONTHS** from the mailing date of this decision to file an oath or declaration in compliance with 37 CFR 1.63 and the surcharge set forth in 37 CFR 1.16(e) for the late filing of the oath or declaration. Extensions of time under 37 CFR 1.136(a) are available. The response should be directed to the attention of Initial Patent Examination Division. Failure to file a timely response will result in the **abandonment** of the application.

It is noted that the filing fee paid for the instant application was applied in prior application No. 09/203,178. The fee should be applied in application No. 09/819,083.

After mailing of this decision, USPTO records will be corrected to show that the \$355.00 filing fee paid on February 15, 2001, was paid in application No. 09/819,083, not in application No. 09/203,178, and for charging the \$130.00 petition fee to deposit account No. 03-1952, as authorized in the petition.

The application will then be forwarded to Initial Patent Examination Division for further processing as a divisional application filed under 37 CFR 1.53(b), not under 37 CFR 1.53(d), with a filing date of February 15, 2001, using the application papers filed on February 15, 2001, and the oath or declaration filed in response to this decision.

Telephone inquiries related to this decision should be directed to the undersigned at (703) 306-5586.



Eugenia A. Jones

Senior Legal Advisor


Office of Patent Legal Administration

Office of the Deputy Commissioner

for Patent Examination Policy

EJ/vb


cc: JONATHAN BOCKMAN
MORRISON & FOERSTER LLP
2000 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, D.C. 20006-1888



PATENT
Docket No. 509582000211

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on December 17, 2001.


Barry C. Kinney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David H. MCDANIEL

Serial No.: 09/819,083

Filing Date: February 15, 2001

For: PROCESS FOR TREATMENT OF
PSORIASIS

Examiner: Not yet assigned

Group Art Unit:

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

TRANSMITTAL LETTER FOR MISSING PARTS OF APPLICATION

Box Missing Parts

Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Decision Granting Petition dated October 15, 2001, attached please find:

- ☒ A combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$65.00 as set forth in 37 C.F.R. § 1.16(e).
- ☐ An Assignment for recording. Separate cover sheet attached.
- ☐ An Information Disclosure Statement.
- ☐ A verified English translation of the application, and the \$130.00 fee as set forth in 37 C.F.R. § 1.17(k).
- ☒ Other: Copy of the Decision Granting Petition letter.

The filing fee has been calculated as follows:

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	- 20 =		x \$18.00	\$0
INDEPENDENT CLAIMS	- 3 =		x \$84.00	\$0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$0
			BASIC FEE	\$15.00 ¹
			TOTAL OF ABOVE CALCULATIONS =	\$15.00
Reduction by 1/2 for filing by small entity (Note 37 C.F.R. §§ 1.9, 1.27, 1.28). If applicable, verified statement must be attached.				\$
SURCHARGE FOR FILING MISSING PARTS				\$65.00
			TOTAL =	\$80.00


☒ Charge \$80.00 to **Deposit Account No. 03-1952** Reference: 50958200211.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 and 1.17 that may be required by this transmittal and associated documents, or to credit any overpayment to **Deposit Account No. 03-1952**. A duplicate copy of this transmittal is enclosed for that purpose.

Respectfully submitted,


Dated: December 17, 2001

By:


Wayne C. Jaeschke, Jr.
Registration No. 38,503

Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 887-1545
Facsimile: (202) 263-8396

¹ This is the difference between the fee paid for the instant application (\$355.00) and the current basic filing fee (\$370.00).



RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

PATENT
Docket No. 509582000211

DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: PROCESS FOR TREATMENT OF PSORIASIS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on February 15, 2001 as United States Application Serial No. 09/819,083.

I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
*	

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
*09/203,178	02/15/2001	<input checked="" type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

I hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Lisa A. Amii (Reg No. 48,199)	Randolph Ted Apple (Reg No. 36,429)
Mehran Arjomand (Reg No. 48,231)	Laurie A. Axford (Reg No. 35,053)
Sanjay S. Bagade (Reg No. 42,280)	Erwin J. Basinski (Reg No. 34,773)
Shantanu Basu (Reg No. 43,318)	Richard R. Batt (Reg No. 43,485)
Vincent J. Belusko (Reg No. 30,820)	Jonathan Bockman (Reg No. 45,640)
Kimberly A. Bolin (Reg No. 44,546)	Barry E. Bretschneider (Reg No. 28,055)
Tyler S. Brown (Reg No. 36,465)	Nicholas Buffinger (Reg No. 39,124)
A. Randall Camacho (Reg No. 46,595)	Mark R. Carter (Reg No. 39,131)
Robert K. Cerpa (Reg No. 39,933)	Peng Chen (Reg No. 43,543)
Alex Chartove (Reg No. 31,942)	Thomas Chuang (Reg No. 44,616)
Thomas E. Ciotti (Reg No. 21,013)	Cara M. Coburn (Reg No. 46,631)
Matthew M. D'Amore (Reg No. 42,457)	Raj S. Davé (Reg No. 42,465)
Peter Davis (Reg No. 36,119)	David Devernore (Reg No. P-50,128)
Karen B. Dow (Reg No. 29,684)	Stephen C. Durant (Reg No. 31,506)
Carolyn A. Favorito (Reg No. 39,183)	David L. Fehrman (Reg No. 28,600)
Hector Gallegos (Reg No. 40,614)	Thomas George (Reg No. 45,740)
Deborah S. Gladstein (Reg No. 43,636)	Debra J. Glaister (Reg No. 33,888)
Kenneth R. Glick (Reg No. 28,612)	Bruce D. Grant (Reg No. 47,608)
Johnney U. Han (Reg No. 45,565)	Douglas G. Hodder (Reg No. 41,840)
Alan S. Hodes (Reg No. 38,185)	Charles D. Holland (Reg No. 35,196)
Kelvan P. Howard (Reg No. P48,999)	Peter Hsieh (Reg No. 44,780)
Jill A. Jacobson (Reg No. 40,030)	Wayne Jaeschke, Jr. (Reg No. 38,503)
Madeline I. Johnston (Reg No. 36,174)	Parisa Jorjani (Reg No. 46,813)
Ararat Kapouytian (Reg No. 40,044)	Richard C. Kim (Reg No. 40,046)
Cameron A. King (Reg No. 41,897)	Lawrence B. Kong (Reg No. P49,043)
Kawai Lau (Reg No. 44,461)	Glenn Kubota (Reg No. 44,197)
Rimas T. Lukas (Reg No. 46,451)	Michael J. Mauriel (Reg No. 44,226)
Gladys H. Monroy (Reg No. 32,430)	Philip A. Morin (Reg No. P-45,926)
Kate H. Murashige	Mabel Ng (Reg No. P48,922)
Martin M. Noonan (Reg No. 44,264)	Catherine M. Polizzi (Reg No. 40,130)
Phillip Reilly (Reg No. 41,415)	Robert E. Scheid (Reg. No. 42,126)
Debra A. Shetka (Reg No. 33,309)	Terri Shieh-Newton (Reg No. 47,081)
Rebecca Shortle (Reg No. 47,083)	Kevin R. Spivak (Reg No. 43,148)
Stanley H. Thompson (Reg No. 45,160)	Thomas L. Treffert (Reg No. P48,279)
Brenda J. Wallach (Reg No. 45,193)	Michael R. Ward (Reg No. 38,651)
E. Thomas Wheelock (Reg No. 28,825)	Todd W. Wight (Reg No. 45,218)
Eric Witt (Reg No. 44,408)	Frank Wu (Reg No. 41,386)
David T. Yang (Reg No. 44,415)	Peter J. Yim (Reg No. 44,417)
George C. Yu (Reg No. 44,418)	Karen R. Zachow (Reg No. 46,332)


Please direct all communications to:

Wayne C. Jaeschke, Jr.
Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888

Please direct all telephone calls to Wayne C. Jaeschke, Jr. at (202) 778-1446.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


12-7-01
Date


Name: *Dr. David McDaniel
Residence: *3033 Little Haven Road, Virginia Beach, Virginia 23452
Citizenship: *US
Post Office Address: *033 Little Haven Road, Virginia Beach, Virginia 23452



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Paper No. 3

ALEX CHARTOVE
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
1333 NEW HAMPSHIRE AVENUE, N.W., SUITE 400
WASHINGTON, DC 20036

COPY MAILED

OCT 15 2001

OFFICE OF PETITIONS

In re Application of
Dr. David H. McDaniel
Application No. 09/819,083
Filed: February 15, 2001
For: Process for Treatment of Psoriasis

DECISION GRANTING
PETITION

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

This is a decision on the petition filed June 4, 2001, requesting that a divisional Continued Prosecution Application (CPA) (identified in the petition by attorney docket No. 509582000211), deposited February 15, 2001, based on prior application No. 09/203,178 be treated as a divisional application under 37 CFR 1.53(b), rather than under 37 CFR 1.53(d), and be accorded a filing date of February 15, 2001.

The application papers filed February 15, 2001, and identified by attorney docket No. 071340.0019, requested treatment as a CONTINUED PROSECUTION APPLICATION (CPA) under 37 CFR 1.53(d) based on prior application No. 09/203,178. The petition filed June 4, 2001, states that the applicant mistakenly requested a filing under 37 CFR 1.53(d), but a filing under 37 CFR 1.53(b) was intended. Accordingly, the applicant requests that the application be treated as a divisional application under 37 CFR 1.53(b).

It is noted that the application papers filed February 15, 2001, included a complete specification and drawings. Therefore, the papers are presently complete for filing date purposes under 37 CFR 1.53(b). The application papers filed February 15, 2001, were filed while the prior application was still pending. The prior application No. 09/203,178 issued as U.S. Patent No. 6,283,956 on September 4, 2001.

Therefore, on petition, the application papers filed on February 15, 2001, will be treated as a divisional application filed under 37 CFR 1.53(b).

The petition is granted.

The 37 CFR 1.53(b) application has been assigned application No. 09/819,083.

DOCKETED
with Declaration
12/15/01
5/15/02 LD

A courtesy copy of this decision is being mailed to the address identified in the petition. However, it is noted that the correspondence address for the present application is contained in the application papers filed February 15, 2001. The Customer Number identified in the transmittal letter is not a valid Customer Number. No further communications will be mailed to the address provided in the petition unless a power of attorney/change of correspondence address is filed.

It is noted that an oath or declaration under 37 CFR 1.63 is missing. Applicant is given **TWO MONTHS** from the mailing date of this decision to file an oath or declaration in compliance with 37 CFR 1.63 and the surcharge set forth in 37 CFR 1.16(e) for the late filing of the oath or declaration. Extensions of time under 37 CFR 1.136(a) are available. The response should be directed to the attention of Initial Patent Examination Division. Failure to file a timely response will result in the **abandonment** of the application.

It is noted that the filing fee paid for the instant application was applied in prior application No. 09/203,178. The fee should be applied in application No. 09/819,083.

After mailing of this decision, USPTO records will be corrected to show that the \$355.00 filing fee paid on February 15, 2001, was paid in application No. 09/819,083, not in application No. 09/203,178, and for charging the \$130.00 petition fee to deposit account No. 03-1952, as authorized in the petition.

The application will then be forwarded to Initial Patent Examination Division for further processing as a divisional application filed under 37 CFR 1.53(b), not under 37 CFR 1.53(d), with a filing date of February 15, 2001, using the application papers filed on February 15, 2001, and the oath or declaration filed in response to this decision.

Telephone inquiries related to this decision should be directed to the undersigned at (703) 306-5586.


Eugenia A. Jones

Senior Legal Advisor


Office of Patent Legal Administration

Office of the Deputy Commissioner

for Patent Examination Policy

EJ/vb

cc: JONATHAN BOCKMAN
MORRISON & FOERSTER LLP
2000 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, D.C. 20006-1888



RECEIVED
DEC 20 2002
TECHNOLOGY CENTER R3700

ATTORNEY DOCKET: 509582000211

DATE: June 4, 2001

INVENTOR(S): Dr. David H. MCDANIEL

Atty/Secy: JXB7/fyj

SERIAL NO.: Unassigned (Divisional of 09/203,178)


TITLE: PROCESS FOR TREATMENT OF PSORIASIS

Papers enclosed:

- ☒ Petition to Clarify Application Status (2 pages)
- ☒ Copy of Divisional application as filed on February 15, 2001
- ☒ Copy of postcard dated/stamped February 15, 2001
- ☒ This return receipt postcard



RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED
DEC 20 2002
TECHNOLOGY CENTER R3700

ATTORNEY DOCKET: 509582000211

DATE: June 4, 2001

INVENTOR(S): Dr. David H. MCDANIEL

Atty/Secy: JXB7/fyj

SERIAL NO.: Unassigned (Divisional of 09/203,178)


TITLE: PROCESS FOR TREATMENT OF PSORIASIS

Papers enclosed:

- ☒ Petition to Clarify Application Status (2 pages)
- ☒ Copy of Divisional application as filed on February 15, 2001
- ☒ Copy of postcard dated/stamped February 15, 2001
- ☒ This return receipt postcard

DOCKETED

RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE



PATENT
Docket No. 509582000211

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on June 4, 2001.

Faith Jacks
Faith Jacks

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Dr. David H. MCDANIEL

Serial No.: Unassigned
(Divisional of 09/203,178)

Filing Date: February 15, 2001

For: PROCESS FOR TREATMENT OF
PSORIASIS

Examiner: To be assigned

Group Art Unit: To be assigned

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

PETITION TO CLARIFY APPLICATION STATUS

Commissioner for Patents
Washington, D.C. 20231

Sir:

The present petition is to clarify that the above-referenced application is a divisional application, and not a CPA. This application in addition to the applications entitled "Process For Inhibiting Activity, Reducing Size & Destroying Growth Of Sebaceous Gland" and "Process for Stimulating Hair Growth", which were also filed on February 15, 2001 are divisional applications as stated in the body of the transmittal forms, and not CPAs as erroneously stated in the heading of the transmittal form.

Accordingly, applicant requests that a filing receipt with the filing date of February 15, 2001, and a serial number for the divisional application be promptly issued. Attached is a copy

of the divisional application as filed and the postcard verifying the filing of the application on February 15, 2001.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 509582000211. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: June 4, 2001

By:



Jonathan Bockman
Registration No. 45,640

Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 778-1601
Facsimile: (202) 263-8396

RECEIVED


DEC 20 2002

TECHNOLOGY CENTER R3700

The "Received" stamp of the Patent and Trademark Office imprinted hereon acknowledges the filing of:

Duplicate of CPA Request Transmittal; copy of previously filed Information Disclosure Statement, Form PTO-1449 & cited references; Preliminary Amendment; previously filed formal drawings; previously filed Specifications w/claims & Abstract (19 pp.);

prepaid postage postcard -- please stamp & return

Name of Inventor(s): DAVID H. MCDANIEL		<div>Receipt Date & Serial No.</div> 
Title of Invention: PROCESS FOR TREATMENT OF PSORIATIS		
Serial No.: N/A	Filing Date: 02/15/01 HEREWITH	
Docket No: 071340.0019	Atty/Secy: AC/FS	
Client Name: MCDANIEL		
Express Mail Receipt No. <input checked="" type="checkbox"/> EL098882554US	Certificate of Mailing <input type="checkbox"/>	

The "Received" stamp of the Patent and Trademark Office imprinted hereon acknowledges the filing of:

Duplicate of CPA Request Transmittal; copy of previously filed Information Disclosure Statement, Form PTO-1449 & cited references; Preliminary Amendment; previously filed formal drawings; previously filed Specifications w/claims & Abstract (19 pp.);

prepaid postage postcard -- please stamp & return

Name of Inventor(s): DAVID H. MCDANIEL		Receipt Date & Serial No.	
Title of Invention: PROCESS FOR TREATMENT OF PSORIASIS			
Serial No.: N/A	Filing Date: 02/15/01	HEREWITH	
Docket No: 071340.0019	Atty/Secy: AC/FS		
Client Name: MCDANIEL			
Express Mail Receipt No. EL09882540S	<input checked="" type="checkbox"/>	Certificate of Mailing <input type="checkbox"/>	



EXPRESS MAIL
UNITED STATES POSTAL SERVICE™

POST OFFICE TO ADDRESSEE

EL0988882554US

ORIGIN (POSTAL USE ONLY)		Day of Delivery		Flat Rate Envelope	
PO ZIP Code		<input checked="" type="checkbox"/> First	<input type="checkbox"/> Second	<input type="checkbox"/>	
Date In				Postage	
Mo. Day Year		<input type="checkbox"/> 12 Noon	<input type="checkbox"/> 3 PM	\$ 7.00	
Time In		Military		Return Receipt Fee	
<input type="checkbox"/> AM <input type="checkbox"/> PM		<input type="checkbox"/> 2nd Day	<input type="checkbox"/> 3rd Day		
Weight		Int'l Alpha Country Code		COD Fee	Insurance Fee
lbs. ozs.		Acceptance Clerk Initials		Total Postage & Fees	
No Delivery				\$	
<input type="checkbox"/> Weekend <input type="checkbox"/> Holiday					

SEE REVERSE SIDE FOR
SERVICE GUARANTEE AND
INSURANCE COVERAGE LIMITS



Customer Copy

CUSTOMER USE ONLY

METHOD OF PAYMENT:

Express Mail Corporate Acct. No.

Federal Agency Acct. No. or
Postal Service Acct. No.

☐ **WAIVER OF SIGNATURE (Domestic Only)** Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

☐ **NO DELIVERY** ☐ Weekend ☐ Holiday

Customer Signature

FROM: (PLEASE PRINT)

PHONE ()

204 827-4160

Mr. & Mrs. George E. SO.
11200 W. Harpeth Ave. Apt. 400
Nashville, N.C. 20016

TO: (PLEASE PRINT)

PHONE ()

ATTN: FOR CPA
Association Commissioner for Reports
Washington, D.C. 20231

FOR PICKUP OR TRACKING CALL 1-800-222-1811

www.usps.com



Label 11-B September 1996

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

CHECK NO. 229599

YOUR INVOICE NO.	INVOICE DATE	CLIENT NO.	MTR NO.	AMOUNT	DESCRIPTION	CHECK NO. REQUESTOR
CO020701	02/08/01	071340	0001	\$ 355.00	PAYMENT OF CPA/DIVISIONAL AP FOR CLAIM 18	A. CHART

DETACH STATEMENT BEFORE DEPOSITING CHECK

THIS DOCUMENT CONTAINS SECURITY FEATURES - SEE BACK FOR DETAILS

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

INCLUDING PROFESSIONAL CORPORATIONS

1333 NEW HAMPSHIRE AVENUE, N.W.

WASHINGTON, DC 20036

(202) 887-4013

FIRST UNION NATIONAL BANK OF WASHINGTON, DC
Washington, DC 20005

CHECK NO. 229599

15-122/540

PAY *Three Hundred Fifty-Five & no/100 Dollars*

DATE 02/08/2001
AMOUNT OF CHECK
\$*****355.00

VOID AFTER 6 MONTHS

TO THE ORDER OF

COMMISSIONER OF PATENTS & TRADEMARKS

James H. Henry
AUTHORIZED SIGNATURE

⑈229599⑈ ⑆054001220⑆2000037752400⑈



PATENT
UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 071340.0009)

In the Application of:

David H. McDaniel

Serial No.: 09/203,178

Filing Date: November 30, 1998

For: REDUCTION, ELIMINATION, OR
STIMULATION OF HAIR GROWTH

§ Group Art Unit: 3739

§ Examiner: Ahmed Farah

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

INFORMATION DISCLOSURE TRANSMITTAL LETTER

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, we are enclosing herewith a resubmission of:

1. This transmittal Letter;
2. An Information Disclosure Statement (2 pp.);
3. Form PTO-1449 (18 pp);
4. One Hundred & Twenty-One (121) references; and,
5. A pre-paid postage return postcard.


No fees are believed to be due with regard to this re-submission of the information disclosure statement. However, if any additional fees are deemed necessary, the Commissioner is authorized to charge said fees, or to credit any overpayments, to Akin, Gump, Strauss, Hauer & Feld, L.L.P., Deposit Account No. 01-0657 (071340.0009).

Respectfully Submitted,

Date: June 20, 2000

By: Alex Chartove

Reg. No.: 31,942



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re Application of:

David H. McDaniel

Serial No.: 09/203,178

Filed: November 30, 1998

For: REDUCTION, ELIMINATION
OR STIMULATION OF HAIR
GROWTH

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Group Art Unit: 3739

Examiner: Ahmed Farah

Atty Dkt: 071340.0009

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

COURIER DELIVERY Certification	
I hereby certify that this correspondence is being deposited with the WASHINGTON EXPRESS COURIER SERVICE FOR HAND DELIVERY TO: 2011 S. Clark Place, Rm. 1B03 Envelope addressed to: Commissioner of Patents & Trademarks, Washington, D.C. 20231, on the date below:	
June 20, 2000 Date	 Frances Sebuabey

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith patents, publications or other information, which may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR §§1.56, 1.97 and 1.98.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (§1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b).

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner.

Form PTO - 1449 is enclosed herewith (18 pages).

Legible copies of the documents listed on Form PTO-1449 accompany this Information Disclosure Statement.

The present Information Disclosure Statement is a resubmission of the original filed February 19, 1999 which was filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fee from Akin, Gump, Strauss, Hauer & Feld, L.L.P. Deposit Account No. 01-0657.

It is respectfully requested that this Information Disclosure Statement and the documents listed on attached Form PTO-1449 be considered by the Examiner, be made a part of the official record, and be cited in the issued patent.

Respectfully submitted,



Alex Chartove

Reg. No. 31,942

ATTORNEY FOR APPLICANTS


Date: June 20, 2000

Akin, Gump, Strauss, Hauer & Feld, L.L.P.
1333 New Hampshire Avenue, N.W.
Washington, D.C. 20036

The "Received" stamp

Patent and Trademark Office unprinted hereon acknowledges the filing of:

Information Disclosure Statement;
PTO Form 1449 - 18 pages;
121 cited references;



Name of Inventor(s): David H. McDaniel		Receipt Date & Serial No.
Title of Invention: Reduction Elimination or		
Serial No.: 6/205,178	Filing Date: 11/30/98	
Docket No: 71340.0009	Att/Secy: AC GC	
Client Name: McDaniel		
Express Mail Receipt No. <input type="checkbox"/>	Certificate of Mailing <input type="checkbox"/>	
Hand Delivery 2/9/99		

RECEIVED


DEC 20 2002


TECHNOLOGY CENTER R3700

The "Received" stamp of the Patent and Trademark Office unprinted hereon acknowledges the filing of:

Information Disclosure Statement;
PTO Form 1449 - 18 pages;
121 cited references

Name of Inventor(s): David H. McDaniel		Receipt Date & Serial No.
Title of Invention: Reduction Elimination or		
Serial No.: 6/205,178	Filing Date: 11/30/98	
Docket No: 71340.0009	Att/Secy: AC GC	
Client Name: McDaniel		
Express Mail Receipt No. <input type="checkbox"/>	Certificate of Mailing <input type="checkbox"/>	
Hand Delivery 2/9/99		





Attorney Docket
No.: 071340.0009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

David H. McDaniel)

Serial No.: 09/203,178)

Filing Date: November 30, 1998)

For: REDUCTION, ELIMINATION,
OR STIMULATION OF HAIR
GROWTH)

Art Group Unit: 3739

Examiner: Unassigned

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §1.56, the applicant submits the following references appearing on the attached PTO Form-1449, which the Examiner may consider to be material to the examination of the above-referenced application. It is requested that these references be considered and be made of record in the above-identified application.

The Information Disclosure Statement is being filed before receipt of an Official Action on the merits. Accordingly, no fee is due.

Respectfully submitted,

Date: 2/19/99

By: Alex Chartove
Alex Chartove
Registration No. 31,942


Akin, Gump, Strauss, Hauer & Feld, L.L.P.
1333 New Hampshire Avenue, N.W.
Suite 400
Washington, DC 20036
(202) 887-4149

I hereby certify that this correspondence is being deposited with the United States
Postal Service with sufficient postage as first class mail in an envelope addressed to
the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on _____
2/19/99

Alex Chartove, Reg. No. 31,942

Alex Chartove
(signature)

2/19/99
(date)

U.S. Patent and
Trademark Office
IDS

ATTORNEY DOCKET NO.

340.0009

SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998

ART GROUP: 3739

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate
	4,458,678	07/10/84	Yannas et al.			
	4,546,743	03/03/87	Parris			
	4,888,354	12/19/89	Chang et al.			
	4,930,504	06/05/90	Diamantopoulos et al.			
	4,959,912	11/13/90	Kelman et al.			
	5,021,452	06/04/91	Sasse et al.			
	5,198,465	03/30/93	Dioguardi			
	5,256,480	11/30/93	Naughton et al.			
	5,332,802	07/26/94	Kelman et al.			
	5,366,498	11/22/94	Brannan et al.			

RECEIVED
DEC 20 2002

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No
97/7751	08/28/97	South Africa			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>Lasers in Surgery and Medicine</u> , 21:262-268 (1997), Improvement of Host Response to Sepsis by Photobiomodulation, Wei Yu et al. (marked up)
	<u>J. Dermatol. Surg. Oncol.</u> , 13:2, February, 1987, Biostimulation of Wound Healing by Lasers: Experimental Approaches in Animal Models and in Fibroblast Cultures, R. Patrick Abergel et al. (marked up)
	<u>Lasers in Surgery and Medicine</u> , 12:528-537 (1992), Power Density and Exposure Time of He-Ne Laser Irradiation are More Important than Total Energy Dose in Photo-Biomodulation of Human Fibroblasts In Vitro, Hans M.F.L. van Breugel et al.
	<u>Skin Barrier Principles of Percutaneous Absorption</u> , Hans Schaefer et al., 1996, pp. 153 and 175 (marked up)
	<u>Skin Pharmacol</u> , 1994; 7:130-139, High-Frequency Sonophoresis: Permeation Pathways and Structural Basis for Enhanced Permeability, Gopinathan K. Menon et al. (marked up)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,173

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1993 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate
	5,397,352	03/14/95	Burres			
	5,445,145	08/29/95	Sellinger			
	5,445,534	08/19/95	Keller			
	5,460,939	10/24/95	Hansbrough Et al.			
	5,591,444	01/07/97	Boss, Jr.			
	5,560,836	08/26/97	Knowlton			
	5,560,850	08/26/97	Boss, Jr.			
	5,565,372	09/09/97	Boss, Jr.			
	5,755,752	05/26/98	Segal			

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	Anesthesiology, V. 78, No. 6, June, 1993, Use of Ultrasound to Enhance the Local Anesthetic Effect of Topically Applied Aqueous Lidocaine, Katsuro Tachibana et al. (marked up)
	Journal of the American Podiatric Medical Association, Vol. 82, No. 8, August, 1992, Hydrocortisone Phonophoresis, A Literature Review, Joseph T. Newman et al. (marked up)
	Science, Vol. 269, August, 1995, Ultrasound-Mediated Transdermal Protein Delivery, Samir Mitragotri et al. (marked up)
	Pharmaceutical Research, Vol. 8, No. 2, 1991, Influence of Ultrasound on the Percutaneous Absorption of Nicotinate Esters, Heather A. Benson et al. (marked up)
	Physiotherapy, Vol. 74, No. 11, November, 1988, Transmission of Ultrasound Energy Through Topical Pharmaceutical Products, Heather A. E. Benson et al. (marked up)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998

ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate
	4,767,402	08/30/88	Kost et al.			
	5,037,432	08/06/91	Molinari			
	5,226,907	07/13/93	Tankovich			
	5,231,975	08/03/93	Bommannan et al.			
	5,423,803	06/13/95	Tankovich et al.			
	5,425,728	06/20/95	Tankovich			
	5,520,478	04/15/97	Eckhouse			
	5,543,334	07/01/97	Eckhouse			
	5,558,323	08/19/97	Miller			
	5,569,916	09/23/97	Anderson			

RECEIVED
DEC 20 2002

TECHNOLOGY CENTER R0700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>Journal of Pharmaceutical Sciences</u> , Vol. 84, No. 6, June, 1995, A Mechanistic Study of Ultrasonically-Enhanced Transdermal Drug Delivery, Samir Mitragotri et al. (marked up)
	<u>Pharmaceutical Research</u> , Vol. 9, No. 8, 1992, Sonophoresis. II. Examination of the Mechanisms of Ultrasound-Enhanced Transdermal Drug Delivery, D. Bommannan et al. (marked up)
	<u>Pharmaceutical Research</u> , Vol. 9, No. 4, 1992, Sonophoresis. I. The Use of High-Frequency Ultrasound to Enhance Transdermal Drug Delivery, D. Bommannan et al. (marked up)
	The International Congress of Esthetics, October 25-27, 1997, convention program
	<u>Cosmetics & Toiletries</u> , Vol. 113, June, 1998, Ultrasonic Radiation for Hair Treatments, Miklos M. Breuer

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate
	5,583,380	11/04/97	Eckhouse			
	5,686,112	11/11/97	Liedtke			
	5,752,949	05/19/98	Tankovich et al.			
	5,817,089	10/06/98	Tankovich et al.			
	5,843,072	12/01/98	Furumoto et al.			

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>J. Appl. Cosmetol.</u> , Vol. 15, 147-159, Oct.-Dec. 1997, Enhancing the Glycolic Acid Efficacy by Piezoelectric Vibrations, P. Morganti et al. (marked up)
	<u>Rheumatology and Rehabilitation</u> , 1975, 14, 237, The Stimulation of Protein Synthesis in Human Fibroblasts by Therapeutic Ultrasound, W. Harvey et al. (marked up)
	<u>Physical Therapy</u> , Vol. 75, No. 7, July, 1995, In Vitro Effects of Therapeutic Ultrasound on the Nucleus of Human Fibroblasts, Patrick G. De Jeyne et al.
	<u>The Lancet</u> , July 25, 1987, A Controlled Trial of Weekly Ultrasound Therapy in Chronic Leg Ulceration, M. J. Callam et al., pp. 204-206 (marked up)
	<u>Am. J. Phys. Med. Rehabil.</u> , Vol. 68, No. 6, December, 1989, The Effects of Therapeutic Ultrasound on Tendon Healing, Chukuka S. Enwemeka

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

RECEIVED
DEC 20 2002
TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>Acta Chirurgiae Plasticae</u> , 19, 3-4, 1977, Ultrasonic Effect on Collagen Synthesis and Deposition in Differently Localized Experimental Granulomas, J. E. Purkyně (marked up)
	<u>Infections in Surgery</u> , September, 1982, Stimulation of Tissue Repair by Therapeutic Ultrasound, Mary Dyson
	<u>Arch Phys Med Rehabil.</u> , Vol. 73, July, 1992, Low-Dose Ultrasound Effects on Wound Healing: A Controlled Study with Yucatan Pigs, Nancy M. Syl, et al. (marked up)
	<u>Physiotherapy</u> , April, 1978, Vol. 64, No. 4, Stimulation of Tissue Repair by Ultrasound: A Survey of the Mechanisms Involved, Mary Dyson et al. (marked up)
	<u>Acta Chirurgiae Plasticae</u> , 15, 2, 1973, Strengthening of Sutured Skin Wound with Ultrasound in Experiments on Animals, V. Drastichova et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A circular stamp from the Office of Intellectual Property (OIP). The text "OIP" is at the top, "JC10" is at the top right, "DEC 04 2002" is in the center, and "PATENT & TRADEMARK" is at the bottom. The stamp is partially overlapping a document with a grid pattern.[illegible]

		Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

(Including Author, Title, Date, Pertinent Pages, etc.)

		Ultrasonics, January, 1980, The Role of Ultrasound-Induced Cavitation in the In-Vitro Stimulation of Collagen Synthesis in Human Fibroblasts, D. F. Webster et al. (marked up)
		Ultrasonics in Med. & Biol., Vol. 4, pp-343-351, The Role of Cavitation in the In Vitro Stimulation of Protein Synthesis in Human Fibroblasts by Ultrasound, D. F. Webster et al. (marked up)
		J. Dermatol Sci., March, 1996, 11(3):250-253, Ascorbic Acid Preferentially Enhances Type I and III Collagen Gene Transcription in Human Skin Fibroblasts, Takima S. Pinnel (Abstract)
		J. Photochem Photobiol B, February, 1993; 17(2):109-114, Photodynamic Effects on the Nuclear Envelope of Human Skin Fibroblasts, B. Kramer et al. (Abstract)
		J. Biochem (Tokyo), November, 1984; 96(5):1491-1500, Hemoprotein H-450 Identified as a Form of Cytochrome P-450 Having an Endogenous Ligand at the 6 th Coordination Position of the Heme, T. Omura (Abstract)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998

ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate

RECEIVED
DEC 20 2002
TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

		Laryngoscope, December, 1987, 97(12):1454-1459, Biostimulative Effects of Nd:YAG Q-Switch Dye on Normal Human Fibroblast Cultures: Study of a New Chemosensitizing Agent for the Nd:YAG Laser, D. J. Castro et al. (Abstract)
		Vojnosanit Pregl., November, 1995; 52(6):539-546, Stimulatory Effect of Low-Power Density He-Ne Radiation on Human Fibroblasts In Vitro, M. Mrnjak et al. (Abstract)
		Ann Plast Surg, January, 1987; 18(1):47-50, Biostimulation of Wound Healing In Vivo by a Helium-Neon Laser, R. F. Lyons et al. (Abstract)
		Lasers Surg Med, 1997; 20(1):56-63, Effects of Photostimulation on Wound Healing in Diabetic Mice, W. Yu et al. (Abstract)
		Artif Cells Blood Substit Immobil Biotechnol, July, 1998; 26(4):437-439, In Vitro Experimental Research of Rabbit Condocytes Biostimulation with Diode Laser Ga-Al-As: a Preliminary Study, G. Morrone et al. (Abstract)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

RECEIVED
DEC 20 2002
TECHNOLOGY CENTER #3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>Lasers in Surgery and Medicine</u> , 22:281-287 (1998), Laser Photostimulation of Collagen Production in Healing Rabbit Achilles Tendons, G. Kesava Reddy et al. (Abstract)
	<u>Lasers in Surgery and Medicine</u> , 22:294-301 (1998), Stimulatory Effect of 660 nm Low Level Laser Energy on Hypertrophic Scar-Derived Fibroblasts: Possible Mechanisms for Increase in Cell Counts, Cecilia Webb et al. (Abstract)
	<u>Lasers Surg Med</u> , 1992; 12(5):528-537, Power Density and Exposure Time of He-Ne Laser Irradiation are More Important than Total Energy Dose in Photo-Biomodulation of Human Fibroblasts In Vitro, M. H. Van Breugel et al. (Abstract)
	<u>Vojnosanit Pregl</u> , November, 1995; 52(6):539-546, Stimulatory Effect of Low-Power Density He-Ne Laser Radiation on Human Fibroblasts In Vitro, M. Hrnjak et al. (Abstract)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

RECEIVED
DEC 20 2002
TECHNOLOGY CENTER R3706

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	Dermatol Surg., 1998; 24:1383-1386, The Use of Low Energy Photon Therapy (LEPT) in Venous Leg Ulcers: A Double-Blind Placebo-Controlled Study, Aditya K. Gupta et al.
	Lasers Surg. Med., 1997; 20(2):131-41, Thermal Damage Assessment of Blood Vessels in a Hamster Skin Flap Model by Fluorescent Measurement of a Liposome-dye System, S. Mordon et al.
	Lasers Surg. Med., 1997; 21(4):365-73, Selective Laser Photocoagulation of Blood Vessels in a Hamster Skin Flap Model Using a Specific ICG Formulation, S. Mordon et al.
	Journal of Drug Targeting, 1994, Vol. 2, pp. 405-410, Liposomes: A Novel Topical Delivery System for Pharmaceutical and Cosmetic Applications, N. Weiner et al.
	Pharmaceutical Research, 1992, Vol. 9, pp. 629-635, Adsorption of Fluorescein Dyes on Albumin Microspheres, Kamel Egbaria et al.

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	Pharmaceutical Research, Vol. 10, No. 12, 1993, Site-Specific Drug Delivery to Pilosebaceous Structures Using Polymeric Microspheres, Alain Rolland et al.
	Journal of Pharmaceutical Sciences, Vol. 79, No. 6, 1990, Relationship Between Contact Time of Applied Dose and Percutaneous Absorption of Minoxidil from a Topical Solution, James Ferry et al.
	Journal of Pharmaceutical Sciences, Vol. 81, No. 8, 1992, Drug and Vehicle Deposition from Topical Applications: Use of In Vitro Mass Balance Technique with Minoxidil Solutions, Jui-Chen Tsai et al.
	Journal of Pharmaceutical Sciences, Vol. 78, No. 5, 1989, Transdermal Iontophoretic Drug Delivery: Mechanistic Analysis and Application to Polypeptide Delivery, V. Srinivasan et al.
	Science, Vol. 270, 1995, Chemical Generation of Acoustic Waves: A Giant Photoacoustic Effect, Muxiong Chen et al.

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>The Journal of Investigative Dermatology</u> , Vol. 103, No. 2, 1994, Effects of Ascorbic Acid on Proliferation and Collagen Synthesis in Relation to the Donor Age of Human Dermal Fibroblasts, Charlotte Phillips et al.
	<u>Journal of Pharmaceutical Sciences</u> , Vol. 58, No. 9, 1969, Enhancement of Percutaneous Absorption by the Use of Volatile: Nonvolatile Systems as Vehicles, M. F. Goldman et al.
	<u>Xenobiotica</u> , 1987, Vol. 17, No. 9, 1113-1120, Deposition of Viprostol (a Synthetic PBE2 Vasodilator) in the Skin Following Topical Administration to Laboratory Animals, G. Nicolson et al.
	<u>Meth and Find Exp Clin Pharmacol</u> , 1989; 11(10): 643-646, Percutaneous Absorption of Coumarin, Griseofulvin and Propranolol Across Human Scalp and Abdominal Skin, Wolfgang Ritschel et al.
	<u>The Journal of Investigative Dermatology</u> , Vol. 99, No. 1, 1992, Topical Delivery Enhancement with Multilamellar Liposomes into Pilosebaceous Units: I. In Vitro Evaluation Using Fluorescent Techniques with the Hamster Ear Model, Linda Lieb et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 20 2002


TECHNOLOGY CENTER R3700

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998

ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>Arch Dermatol</u> , Vol. 121, Feb. 1985, Percutaneous Absorption of Minoxidil in Man, Thomas Franz
	<u>Skin Pharmacol</u> , 1991; 4:230-234, Percutaneous Penetration of Methyl Nicotinate at Three Anatomic Sites: Evidence for an Appendageal Contribution to Transport?, Ethel Tur et al.
	<u>Journal of Pharmaceutical Sciences</u> , Vol. 79, No. 7, 1990, Iontophoresis of Polypeptides: Effect of Ethanol Pretreatment of Human Skin, V. Srinivasan et al.
	<u>Skin Pharmacol</u> , 1994; 7:245-256, Percutaneous Absorption of Estradiol and Progesterone in Normal and Appendage-free Skin of the Hairless Rat: Lack of Importance of Nutritional Blood Flow, F. Hueber et al.
	<u>Journal of Pharmaceutical Sciences</u> , Vol. 82, No. 2, 1993, Iontophoretic Transdermal Delivery of Salicylic Acid and Lidocaine to Local Subcutaneous Structures, Parminder Singh et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

[illegible]

		Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

(Including Author, Title, Date, Pertinent Pages, etc.)

		Arch Dermatol Res., 267, 229-235 (1980), Variations in Percutaneous Absorption of Testosterone in the Rhesus Monkey Due to Anatomic Site of Application and Frequency of Application, Ronald Wester et al.
		Pharmaceutical Research, Vol. 9, No. 7, 1992, Transdermal Delivery of Insulin to Alloxan-Diabetic Rabbits by Ultrasound Exposure, Katsuro Tachibana
		Photodermatol Photoimmunol Photomed, 1991; 8: 129-134, Effects of Ultraviolet A and B on the Skin Barrier: a Functional, Electron Microscopic and Lipid Biochemical Study, P Lehmann et al
		Arch Dermatol, Vol. 127, January 1991, Ultrasound Localization of Calcium in Psoriatic and Normal Human Epidermis, Gopinathan K. Menon et al.
		British Journal of Dermatology, 1982, 107, 35-42, A Fluorescence Photographic Photometric Technique to assess Stratum Corneum Turnover Rate and Barrier Function In Vivo, A Finlay et al

DATE CONSIDERED

RECEIVED


DEC 20 2002

TECHNOLOGY CENTER R3700

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	<u>Physiological Review</u> , Vol. 51, No. 4, 1971, Permeability of the Skin, Robert Scheuplein et al.
	<u>Mag.-Bull.</u> , 1987, pp. 130-131, Noise-Induced Hearing Loss in Humans as a Function of Serum Mg Concentration, Z. Joachims et al.
	<u>Clin. Cardiol.</u> , 20, 285-290 (1997), Electrophysiology, Pacing and Arrhythmia, Dan Roden, MD
	<u>The Yale Journal of Biology and Medicine</u> , 58 (1985), 553-559, Regulation of Collagen Biosynthesis by Ascorbic Acid: A Review, Sheldon Pinnell
	<u>Archives of Biochemistry and Biophysics</u> , Vol. 295, No. 2, 1992, pp. 397-403, Ascorbic Acid and Transforming Growth Factor- β 1 Increase Collagen Biosynthesis via Different Mechanisms: Coordinate Regulation of Pro α 1(I) and Pro α 2(I) Collagens, Charlotte Phillips et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER

[illegible]

		Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

(Including Author, Title, Date, Pertinent Pages, etc.)

		Archives of Biochemistry and Biophysics, Vol. 307, No. 2, 1993, pp. 331-335, Ascorbic Acid and Collagen Synthesis: Rethinking a Role for Lipid Peroxidation, Douglas Darr et al.
		Toxicology and Applied Pharmacology, 94, 93-103, 1988, In Vitro percutaneous Absorption in Mouse Skins: Influence of Skin Appendages, J. Kao et al.
		Journal of Pharmaceutical Sciences, Vol. 80, No. 5, 1991, Follicles Play an Important Role in Percutaneous Absorption, Brigitte Illel et al.
		Journal of Pharmaceutical Sciences, Vol. 81, No. 7, 1992, Studies of In Vitro Skin Permeation and Retention of a Leukotriene Antagonist from Topical Vehicles with a Hairless Guinea Pig Model, Saran Kumar et al.
		Ultrasound in Med. & Biol., Vol. 22, No. 2, pp. 151-164, 1996, Physical Characteristics and Biological Effects of Laser-Induced Stress Waves, A. Doukas et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

A circular black ink stamp from the Office of Intellectual Property, Jamaica. The text "O I P E JC10" is curved along the top inner edge. The date "DEC 04 2002" is stamped in the center. The text "PATENT & TRADE MARK" is curved along the bottom inner edge. The words "Office of Intellectual Property" and "JAMAICA" are written vertically along the right outer edge.[illegible]

		Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

(Including Author, Title, Date, Pertinent Pages, etc.)

	J. Soc. Cosmet. Chem., 29, 265-282, May, 1978, Autoradiographic Study on Percutaneous Absorption of Several Oils Useful for Cosmetics, M. Suzuki et al.
	Lasers in Surgery and Medicine, 20:426-432, 1997, Effects of Low-Energy Gallium-Aluminum-Arsenide Laser Irradiation on Cultured Fibroblasts and Keratinocytes, M. Pogrel et al.
	Advance Rehabilitation, July/August 1991, More Than a Thermal Modality: Ultrasound, Stephen Guffey et al.
	Electrotherapy, Vol. 11, No. 4, July/August 1991, Ultrasound: Current Concepts, Nancy Garr
	The Journal for Prevention and Healing Advances, Vol. 9, No. 5, September/October 1996, Promotion of Wound Healing with Electrical Stimulation, Luther Kloth et al.

EXAMINER	DATE CONSIDERED
----------	-----------------

RECEIVED

DEC 20 2002


TECHNOLOGY CENTER R3700

U.S. Patent and
Trademark Office
IDSATTORNEY DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998

ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

	Advance for Physical Therapists, March 23, 1992, Uniformity Needed in Therapeutic Use of Ultrasound, Michelle Pronesti
	JOSPT, Vol. 12, No. 3, March, 1995, Temperature Changes in Deep Muscles of Humans During Ice and Ultrasound Therapies: an In Vivo Study, David Draper et al.
	Reprint from the Journal, Physikalische Medizin und Rehabilitation Heft 9/68, The Combined Application of Ultrasound and Stimulation Currents, K. Gierlich et al.
	Advance Rehabilitation, April, 1995, From Submarines to Rehab: New Developments in Ultrasound, John Murphy
	Department of Anatomy, Guy's Hospital Medical School, London, England, pp. 110-122, The Effect of Ultrasound on the Rate of Wound Healing and the Quality of Scar Tissue, M. Dyson

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED


DEC 20 2002

TECHNOLOGY CENTER R3700

U.S. Patent and
Trademark Office
IDSATTORNEY . DOCKET NO.
071340.0009SERIAL NO.
09/203,178

APPLICANT: David H. McDaniel

FILING DATE: November 30, 1998 ART GROUP: 3739



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

		The Twentieth Annual Pharmaceutics Graduate Student Research Meeting, The University of Missouri-Kansas School of Pharmacy, June 10-12, 1988, The Effect of Ultrasound on the In Vitro Penetration of Ibuprofen Through Human Epidermis, Maulik Nanavaty et al.
		In Vitro Cell. Dev. Biol., 28A:679-681, November-December, 1992, Product-Delivering Liposomes Specifically Target Hair Follicles in Mistocultured Intact Skin, Lingna Li et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 20 2002

TECHNOLOGY CENTER R3700

**CONTINUED PROSECUTION APPLICATION
(CPA REQUEST TRANSMITTAL)**

EL098882554US

Check Box, if applicable:
☐ Duplicate

Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

Attorney Docket No. 071340.0019
First Named Inventor: David H. McDaniel
Express Mail Label No. EL098882554US
Total Pages of Transmittal Form: 2

NEW TITLE: PROCESS FOR TREATMENT OF PSORIASIS

This is a request under 37 CFR 1.53(d) for a continued prosecution application (CPA) which is a
☐ Continuation or ☒ Divisional of pending prior application **09/203,178**, filed on **November 30, 1998**. **Cancel all prior claims except claim 18.**

Anticipated Group/Art Unit 3739, or Class &@, Subclass &@.

- ☐ Enter the unentered Amendment previously filed on &@ under 37 CFR 1.116 in the pending non-provisional application.
- ☐ Request for Nonpublication of Application Under 35 U.S.C. §122(b) (37 C.F.R. §1.213(a)).
- ☒ Substitute Specification (filed with original application).
- ☒ A Preliminary Amendment is enclosed.
- ☐ This application is filed by fewer than all the inventors named in the pending application, 37 CFR 1.53(d)(4). Delete the following inventor(s) named in the prior non-provisional application: &@; &@.
- ☐ A new Power of Attorney is enclosed.
- ☒ Previously filed Information Disclosure Statement, PTO-1449 and cited references are enclosed.
- ☒ Previously filed formal drawings are enclosed.
- ☐ A Petition for Extension of Time along with requisite fee is enclosed.
- ☒ Applicant(s), by its/their undersigned attorney, claim(s) Small Entity Status under 37 C.F.R. §1.27 as ☐ an Independent Inventor, or ☒ a Small Business Concern, or ☐ a Non-Profit Organization.
- ☒ Other: Prepaid return postcard – please stamp & return.

The filing fee is calculated as follows:

			SMALL ENTITY			LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE: \$355			BASIC FEE: \$710	
Total	1-20 =	0	X\$9	\$	OR	X\$18	\$ 0.00
Independent	1-3 =	0	X\$40	\$	OR	X\$80	\$ 0.00
Multiple Dependent Claim(s) Present			\$135	\$	OR	\$270	\$ 0.00
			TOTAL	\$	OR	TOTAL	\$355.00

- [X] A check in the amount of **\$355.00** to cover the filing fee is enclosed.
- [X] The Commissioner is hereby authorized to charge and/or credit **Deposit Account No. 50-1017 (Billing No. 071340.0019)** as noted below. A duplicate copy of this sheet is enclosed.
- [X] Any overpayments or deficiencies in the above-calculated fee.
- [] Filing fee in the amount of \$_____ as calculated above.
- [X] Any additional fees required under 37 C.F.R. § 1.16 and § 1.17.
- [X] In the event that a Petition for Extension of Time is required during the prosecution of this application, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account noted above.

CORRESPONDENCE ADDRESS:

February 15, 2001
(Date)

By: Alex Chartove

Alex Chartove

Registration No. 31,942

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

1333 New Hampshire Avenue, N.W., Suite 400

Washington, D.C. 20036

Telephone: 202-887-4000

Direct Dial: 202 887-4149

Facsimile: 202 887-4288

E-Mail: achartove@akingump.com

[X] Customer Number or Bar Code Label: **000270**

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
David H. McDaniel)	Parent Art Group Unit: 3739
)	
Parent Serial No.: 09/203,178)	Parent Examiner: A. Farrah
)	
Parent Filing Date: November 30, 1998)	
)	
For: REDUCTION, ELIMINATION,)	
OR STIMULATION OF)	
HAIR GROWTH)	
_____)	

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents & Trademarks
Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-referenced application, please amend the application as follows:

IN THE SPECIFICATION:

In the Title of the Invention, please delete the present Title in its entirety and insert therefor --Process for Treatment of Psoriasis--.

IN THE CLAIMS:

Please cancel claims 1 - 6 without prejudice.

Please add new claim 7 as follows:

7. A process for the treatment of psoriasis affecting mammalian skin, comprising:
selecting at least one of a photoactive agent and a photosensitizing agent, the agent having an electromagnetic radiation absorption characteristic enabling the agent to absorb at least a first wavelength of electromagnetic radiation from an electromagnetic radiation source, applying the agent to at least a portion of the mammalian skin affected by psoriasis, exposing the agent to electromagnetic radiation comprising at least the first wavelength of electromagnetic radiation, whereby the agent absorbs the first wavelength of electromagnetic radiation.

REMARKS

Claims 1 - 6 have been canceled. New claim 7 has been added. The Title of the Invention has been changed. Examination and consideration of the application, as amended, are respectfully requested. Allowance of the claim at an early date is solicited.

Applicant notes that new claim 7 corresponds to claim 18 that was canceled from parent application serial number Parent Serial No.: 09/203,178.

It is respectfully submitted that the claim in the present application, as amended, is in condition for allowance.

If for any reason the Examiner finds the application other than in condition for allowance, the Examiner is respectfully requested to call the undersigned attorney at the Washington, D.C. telephone number (202) 887-4149 to discuss the steps necessary for placing the application in condition for allowance.

Respectfully submitted,

Date: February 15, 2001

By: Alex Chartove
Alex Chartove
Registration No. 31,942

Akin, Gump, Strauss, Hauer & Feld, LLP
1333 New Hampshire Avenue, N.W.
Suite 400
Washington, DC 20036
Tel. (202) 887-4149
Fax. (202) 887-4288

REDUCTION, ELIMINATION, OR STIMULATION OF HAIR GROWTH

Field of the Invention

The present invention generally relates to a system for the reduction,
5 elimination or stimulation of hair growth in mammalian skin.

Background of the Invention

There are several known techniques for attempting to reduce, eliminate or
stimulate hair growth in human skin. A few of these known techniques are
scientifically proven and widely accepted as effective. However, their degree of
10 efficacy varies greatly.

There are several processes which may be used for producing
preferential damage of the hair. In one process the target may be natural
melanin pigment in the hair shaft and surrounding supporting tissues. In another
process the target may be an external chromophore or contaminant. Most of
15 these processes tend to damage the hair, either by producing heat or by photo-
acoustical shock waves. These known processes have varying degrees of
effectiveness, but require multiple treatments and, in their current form, produce
only partial permanent hair reduction.

In recent years the use of light sources to reduce or eliminate unwanted
20 hair growth has been developed. One known technique selects a wavelength of
laser light that is well-absorbed by the naturally occurring "native" pigments in
the hair shaft (and perhaps some pigment in parts of the hair duct or hair follicle
cells).

Another known technique uses a short pulsed laser to produce a
25 wavelength that may be absorbed by a "foreign" material or "skin contaminant".
Aspects of this technique are described, for example, in US Patent No.
5,423,803, US Patent No. 5,817,089, US Patent No. 5,425,728, US Patent No.
5,226,907, and US Patent No. 5,752,949, all of which are incorporated by
reference. This contaminant may be applied directly onto the skin and may be

introduced into the empty space surrounding the hair shaft. One contaminant that has been used is carbon graphite in particulate form. The graphite particles have a diameter that is small enough to enable the particles to drop from the surface of the skin into the free empty spaces between the duct and the hair shaft. The energy from a laser may then interact with the contaminant particles. This causes injury to surrounding tissues whose function is to support the growth of the hair shaft. This tends to reduce or eliminate hair growth.

These contaminant particles are not physically incorporated into the hair shaft or into the surrounding hair follicle, hair bulge or hair duct cells. Nor do these contaminant particles chemically, immunologically, biologically or otherwise interact, react or complex with the hair shafts or tissue cells. The contaminant particles simply physically occupy the space surrounding the hair shaft.

Another known hair removal technique is to use a pulsed electromagnetic radiation source to produce a wavelength that may be absorbed by hair, as described, for example, in US Patent No. 5,683,380, which is incorporated by reference.

There are problems with present light and laser hair removal techniques. Known melanin targeting systems work reasonably well and are reasonably safe only when the color of the hair is very dark and when the skin is very light and not tanned. Virtually all light sources which tend to target melanin are also inherently absorbed by the overlying and surrounding skin. At present, these light sources cannot be safely used at optimal very high power settings for people with darker skin or even people with a dark tan.

Dyeing the hair allows increased damage to the hair target, helps confine damage to the hair target, and enables the use of power settings that are not so high as to damage surrounding and overlying skin. Treatments which target melanin inherently do not work well on light hair, since there is not enough

natural pigment to absorb enough energy to damage hair even if the power is quite high. Using hair dye enables this obstacle to be overcome.

A known hair removal process which uses a 1064 nm laser to produce a wavelength that may be absorbed by a skin contaminant appears to be safe on all skin colors, including darker skin colors. However, this safety is a consequence of there being very little melanin absorption. It is therefore necessary to add graphite particles in oil contaminant lotion before laser treatment. This graphite particle lotion does not enter into the hair shaft itself. Instead, the graphite lotion tends to occupy empty spaces surrounding the hair shaft as it sits in the hair duct. This presents a problem. Either an insufficient or sub-optimal number of graphite particles penetrate into the hair duct, or an insufficient amount of damage is caused by the graphite particles. Consequently, many treatments tend to be required before an acceptable result is achieved.

15 **Summary of the Invention**

The present invention enables the safe treatment of virtually all hair colors (including light hair) on virtually all skin colors (including light, untanned skin).

The present invention may be advantageously used with virtually any laser or light mediated hair removal device or process. The present invention tends to enhance damage to unwanted hair without significantly increasing adverse side effects or compromising safety. The present invention enables the use of existing light sources, by selecting a dye which is well absorbed by that light source.

The present invention encompasses all dyes or agents which may, by any mechanism, be attached or incorporated into the hair shaft or the hair duct cells or any part of the hair follicle cells or cells of the supporting tissues, including blood vessels supplying the hair follicle. These agents, and their breakdown products, are preferably non-toxic. Each agent may be appropriately matched to a corresponding light source.

The present invention may be used in conjunction with known laser or light sources. The present invention, in a preferred embodiment, tends to enhance laser or light activated hair removal. The present invention encompasses using one process to treat hair, and then going back over the area
5 (or simultaneously) treating with two different light sources or simultaneously treating with single or multiple sources.

The present invention, in a preferred embodiment, is able to enhance virtually any hair removal process. Enhancement may occur, for example, by enabling more hair to be removed, or by eliminating hair for a longer period of
10 time, or by increasing the probability (or percentage) of hairs that are permanently destroyed.

Brief Description of the Drawings

A detailed description of a preferred embodiment of the present invention will be made with reference to the accompanying drawings.

15 Figure 1a illustrates an example of a hair duct and sebaceous glands without any particles being present.

Figure 1b illustrates an example of a distribution of particles having an average diameter of about one micron in a hair duct and sebaceous glands.

20 Figure 1c illustrates an example of a distribution of particles having an average diameter of about five microns in a hair duct and sebaceous glands.

Figure 1d illustrates an example of a distribution of particles having an average diameter of about fifteen to twenty microns in a hair duct and sebaceous glands.

25 Figure 2 illustrates, in an enlarged view, an example of a distribution of particles having an average diameter of about five microns in a hair duct and sebaceous glands.

Figure 3a illustrates an example of a hair duct and sebaceous glands without any particles being present.

Figure 3b illustrates an example of a distribution of particles having an average diameter of about one micron in a hair duct and sebaceous glands

Figure 3c illustrates an example of a distribution of particles having an average diameter of about one micron in a hair duct and sebaceous glands in which an enzyme has been used to help "unplug" hair follicle openings, thus allowing more particles to penetrate.

Figure 3d illustrates an example of a distribution of particles having an average diameter of about one micron in a hair duct and sebaceous glands in which ultrasound treatment has been used to increase the number of particles in the hair duct and enabled the particles to penetrate the deeper part of the hair duct.

Figure 4a illustrates an example of a hair duct and sebaceous glands prior to hair dying treatment.

Figure 4b illustrates an example of a hair duct and sebaceous glands prior to hair dying treatment and after laser or light treatment.

Figure 4c illustrates an example of a hair duct and sebaceous glands after hair dying treatment.

Figure 4d illustrates an example of a hair duct and sebaceous glands after hair dying treatment and after laser or light treatment using parameters substantially identical to those used in the example illustrated in Figure 4b. The example illustrated in Figure 4b shows less damage than the example illustrated in Figure 4d after otherwise identical treatment.

Figure 5 illustrates, in an enlarged view, an example of a distribution of particles having an average diameter of about one micron encapsulated in microspheres having an average diameter of about five microns in a hair duct and sebaceous glands.

Detailed Description of the Preferred Embodiments

The following detailed description is of the best presently contemplated mode of carrying out the invention. This description is not to be taken in a

limiting sense, but is made merely for the purpose of illustrating the general principles of the invention. The scope of the invention is best defined by the appended claims.

5 In a preferred embodiment, the present invention is directed to a process for producing temporary or permanent reduction or removal, in human or mammalian skin, of some or all of the hairs growing in hair follicles and exiting the skin through hair ducts. In a preferred embodiment the process produces little or no permanent injury or damage to nearby skin tissue. Substantially only the hair follicle and immediately surrounding tissue are damaged.

10 In a process according to one embodiment of the present invention, an agent may be selected which is capable of penetrating the hair ducts and attaching, bonding or otherwise becoming incorporated into the hair shaft, hair follicle, hair bulb or hair duct cells. The agent may be characterized as an active agent in that it performs a function in addition to simply occupying or
15 contaminating the space in the ducts surrounding the hair shaft. The agent may have sufficient optical absorption of a wavelength (or a combination of wavelengths) of a coherent or non-coherent light source which can penetrate the skin adequately to be absorbed by the target agent or the new agent-tissue complex.

20 The area of skin from which unwanted hair is to be removed may be cleansed. After the skin is cleansed, the hair and/or the skin may be treated to improve permeability. This may be accomplished, for example, by treating the hair and/or skin with steam or a hot moist towel to hydrate the skin and hair.

The agent may be applied in sufficient quantity and in suitable form to be
25 incorporated into the target tissue in adequate or optimal amounts to allow the production of the desired tissue effect.

Excess agent may be removed, neutralized, inactivated, decolorized, diluted or otherwise altered so that residual contamination of the

skin or hair duct space by such excess agent is either (a) absent and does not interact with the light or energy source, or (b) present in such small quantity that it provides no clinical effect.

Delivery of the desired agent into the target tissues may be enhanced, facilitated or made possible by the use of enzymes or by the use of ultrasound or phonophoresis either for penetration into the hair duct or the hair follicle or hair bulb cells or to penetrate into the hair shaft itself or surrounding target tissues or to cause the release of the agent from the encapsulated delivery device such as liposomes, polymers, microspheres, etc. so as to cause penetration or attachment of this active agent. The water content or absorption by the hair shaft might be enhanced, to increase the hair shaft diameter and volume or to otherwise enhance the process.

Ultrasound may be used therapeutically to interact directly with the agent or the agent-tissue complex to produce the desired damaged target tissues (to be used alone or in combination with laser or non-laser light sources).

Ultrasound may be used to make graphite penetrate better, for example. A more detailed description of several aspects of the use of ultrasound may be found, for example, in the applicant's co-pending U.S. Patent application serial number 09/087,146 for "Ultrasound Enhancement of Percutaneous Drug Absorption."

Although preferred embodiments of the present invention may use ultrasound and/or laser or light energy, the present invention is not limited to the use of these energy sources. Other sources of energy, including (without limitation) microwave energy and radio frequency energy may also be used.

The targeted skin may be exposed to one or more wavelengths of laser or non-laser light or single or multiple frequencies of ultrasound. A variety of parameters may be used (including pulse duration, energy, single or multiple pulses, the interval between pulses, the total number of pulses, etc.) to deliver sufficient cumulative energy to interact with the agent or tissue complex. This may result in injury, damage or destruction of the hair follicle, hair bulb or the

supporting skin tissue, thereby delaying regrowth of the hairs, or diminishing the hair shaft diameter, or miniaturizing the hair follicles or completely destroying these tissues, resulting in permanent hair removal. Ultrasound may also be used to preheat the target structures, the skin, and/or the hair.

5 The agent may be incorporated into the target tissue by a variety of mechanisms. These mechanisms include, but are not limited to: 1) physical incorporation into the hair shaft or target tissue cells while leaving the chemical structure essentially unaffected, or 2) undergoing a chemical reaction resulting in a new agent-tissue complex which then becomes a target for energy absorption.

10 The process may be a single or multi-step process and may involve the use of cofactors, catalysts, enzymes, or multiple agents which interact to ultimately become or create an active agent or agent-tissue complex.

 Agents may include, without limitation: hair dyes, vegetable dyes, food coloring, fabric dyes, tissue stains, shoe or leather dyes, other plant products
15 (such as flavonols, chlorophyll, carotenoids, enzymes, monoclonal antibodies, any immunological agent, genetically engineered agent, benign infectious agents, whether naturally occurring or genetically engineered (e.g. the bacteria that normally reside on the skin such as acne bacteria, etc.), antibiotics, agents which attach to melanin in the hair shaft or surrounding follicle, bulge or duct
20 cells directly, whether by topical or systemic agents that localize in the target tissues.

 Agents may be delivered in pure form, in solution, in suspension, in emulsions, in liposomes, in synthetic or natural microspheres, microsponges or other known microencapsulation vehicles.

25 The process may include an application of an active agent and treatment with an energy source as a single treatment. Alternatively, treatment with an energy source may be delayed for hours or days after application of an active agent. Application of an active agent may be performed or applied at another location, such as patient's home, prior to the energy treatment.

After an energy treatment has occurred it may be desirable in some situations to remove, neutralize, decolorize or otherwise inactivate any residual active agent.

One preferred embodiment uses a hair dye incorporated into the hair shafts. The dye may be selected to absorb 1064 nm laser light. Depending upon the wavelength of laser light, suitable hair dyes may include, for example, Professional Miss Clairol 52D Black Azure or 51D Black Velvet. Laser pulse durations may be selected with sufficient power density to allow the target tissue to be appropriately damaged.

One known hair removal process uses a solution of graphite in oil lotion and a Q-switched 1064 nm Nd:YAG laser. The solution may be applied to the skin and hair and then the skin and hair may be treated with the laser using known parameters. It may be preferable to use a high repetition rate, such as 8-10 Hertz or higher, and move the laser handpiece slowly enough that pulses are "stacked" in one spot for several pulses before the handpiece is moved to an adjacent spot. It has been found that there is a stair-step like effect of incremental temperature rise in the dyed hairs with the second and third pulses versus a single pulse. A faster repetition rate also tends to help build the heat up faster, and to higher levels. This tends to produce the maximum heat (which is desirable, as long as the heat stays confined to the hair follicle and the immediately adjacent supporting tissues). Since this effect occurs substantially simultaneously with other destructive effects of the process, the damage to hair growth tends to be enhanced. Unlike carbon exploded particles on light impact, the dyes and similar agents may actually remain absorbing for a brief time until they reach a critical temperature at which time they are destroyed or become non absorbers, thus acting as a sort of heat sink for a brief time, allowing more heat to accumulate. Safety remains at about the same level, since dye related damage tends to be confined to target tissues. There is no appreciable change in treatment time.

In an alternative embodiment, a hair dying process similar to that described above may be used with a laser that tends to target melanin rather than graphite contaminant. Such a laser may be, for example, a long pulsed alexandrite or long pulsed ruby or diode laser. In the case of a long pulsed alexandrite laser, tests have been conducted using a Cynosure LPIR version at 755 nm wavelength and 20J/cm² and 20msec pulse duration with a dye that absorbs at 755 nm. Infrared camera analysis of hair treated according to this process shows both relatively higher temperature and also relatively slower cooling of the hair shafts themselves. This allows further heating of the target tissues. It also helps make the treatment safer and probably more effective.

Another preferred embodiment uses a longer pulsed laser in the 750 nm-1000 nm range and appropriate parameters to achieve the desired tissue damage goal.

Another embodiment uses a tissue dye which attaches to, or is incorporated into, a target cell and surrounding tissues. The target tissue may be illuminated with a multi-wavelength non-laser light source using appropriate parameters to achieve the desired tissue damage goal.

Another embodiment uses a light source which is well-absorbed by the melanin naturally present in undyed darker hairs and a hair dye which may be incorporated into the hair shaft. The hair dye will be well-absorbed by the same wavelength of light (or alternatively two or more wavelengths, one for melanin and one or more for the dye) which is absorbed by the undyed hair, resulting in an enhanced or greater injury to the target tissue (or permitting lower treatment energy parameters, resulting in safer treatment than if the hairs were treated without the hair dye). This tends to benefit people having darker skin or tanned skin, by allowing lower treatment energy. For example, a diode laser or LED or non-laser light source could produce a continuous or pseudo-continuous beam of light energy using pulse durations as long as seconds at a wavelength which is absorbed by the native hair pigment and also by the hair dye used. A pulse

duration on the order of between about one and thirty seconds appears to be preferable. This also tends to be a much longer time than is used in most systems in use today.

Another embodiment uses an agent which facilitates cavitation shock waves or a thermal effect, or both. This preferentially damages (or stimulates) the target tissues while minimizing damage (or other adverse effects) on surrounding non-target tissues. This may be used with very short pulsed lasers or light sources or with ultrasound alone.

In one embodiment a process in accordance with the present invention may be used to temporarily or permanently stimulate hair growth in human or mammalian skin. Some or all of the hair follicles in the treatment area may be stimulated to grow, to have their growth cycle accelerated, to prolong the hair growth cycle, to increase the hair shaft diameter, to change the hair shaft color, to stimulate hairs that are in a dormant state or which originate from an area of hair loss or baldness, or to produce a combination of the above-mentioned effects. This tends to involve a lower level of delivered energy than that used for hair reduction. Phonophoresis may be used to deliver other stimulating or growth supporting agents.

In one embodiment a process in accordance with the present invention may be used to provide short or long-term control, improvement, reduction or elimination of acne or other skin diseases. An active agent may be physically or chemically or immunologically incorporated into cells of the sebaceous (oil) glands or into the naturally occurring acne bacteria, yeast or similar organisms which feed on the oil in the oil glands (or sweat glands) or are otherwise relatively benign inhabitants. Improvement in skin disorders may be a direct or indirect result of the application of the agents in this process, as may reduced oiliness of the skin, reduced size or diminished appearance of pores, etc.

Other similar disorders such as folliculitis which involve the pilo-sebaceous (hair/oil gland) unit may also be treated using the present invention.

The present invention may also be used to reduce perspiration, sweating, or hyperhidrosis from eccrine (sweat) glands or apocrine glands. A preferred embodiment of the present invention may be used to treat other skin disorders such as, for example, viral warts, psoriasis, precancerous solar keratosis or skin lesions, hyperhidrosis/excessive sweating, and perhaps skin ulcers(diabetic, pressure, venous stasis).

A preferred embodiment of the present invention may use various microencapsulation processes to deliver active agents. If the diameter of the micro encapsulations is about five microns, then there may be relatively site specific preferential delivery into the sebaceous oil glands or skin surface stratum corneum cells. If the diameter of the microencapsulations is in the range of about one micron, then the active agents may be delivered with a more random distribution between the hair ducts and the oil glands. If the diameter of the microencapsulations is larger, on the order of about 20 microns or greater, then delivery will tend to be restricted primarily to the skin surface. The micro encapsulations may be synthetic or natural. If ultrasound is used to enhance penetration, then the diameters and ultrasound treatment parameters may need to be adjusted according to the applicable principles which allow the estimation of the optimal ultrasound parameters for driving small particles into the skin, skin appendages or skin orifices.

Microencapsulation may be used to improve delivery of known agents such as indocyanine green and particles of carbon or graphite. A known technique for using a laser to produce a wavelength that may be absorbed by indocyanine green for a hair removal treatment process is described, for example, in US Patent No. 5,669,916, which is incorporated by reference. It has been found that by using smaller particles and putting the smaller particles into more uniform diameter microencapsulations, more site specific or uniform targeting may be achieved. A preferred formulation may include indocyanine green or other dyes or agents to form a lipid complex which is fat-loving

(lipophilic). The delivery and clinical effects of agents and dyes such as indocyanine green dye may be refined and enhanced by selecting a carrier or encapsulation having a diameter that increases the probability of preferential delivery to a desired space, and/or that enables interaction with ultrasound to
5 thereby increase the probability of preferential delivery, and/or that selectively attaches to the sebaceous gland and/or hair.

Indocyanine green dye is presently in medical use, appears to be relatively benign, may be activated by red visible lasers (in the 800 nm range) may penetrate deeply enough to reach the oil glands, is used for leg vein and
10 hair removal, and is relatively safe, cheap, and reliable. A known technique for using a laser to produce a wavelength that may be absorbed by indocyanine green for use in a leg vein treatment process is described, for example, in US Patent No. 5,658,323, which is incorporated by reference.

The microsponges containing the active agent may selectively attach, or
15 at least have a chemical affinity for, some part of the oil gland. The ICN dye may be conjugated with lipids, which would then have an affinity for the oil glands. Alternatively, the attachment may occur after the active agent is released from the microsphere, either passively or by attractive or chemical forces. In the case of some microencapsulation carrier vehicles, release may occur after disruption
20 of the vehicle integrity itself, possibly by ultrasound or laser or light or other energy source or perhaps a chemical reaction.

In a preferred embodiment the ICN dye may be mixed with lipids, or put into microsponges (a.k.a. microspheres), and then applied to the skin surface, allowed to sit for a time. Excess dye may be removed, and then the area may be
25 treated with laser light at about 800 nm, between about 0.1 and 100 millisecond pulses and around 1.0-10.0 Joules/cm².

USP 5,817,089 specifies "particles having a major diameter of about 1 micron". It has been discovered, however, that these diameters may not be optimal. A 1993 Pharmaceutical Research journal article by Rolland et al

describes an acne treatment wherein a topical acne drug is delivered with less irritation by putting the drug into synthetic polymer microsphere sponges. This article reported that an optimal diameter for site-specific delivery into sebaceous oil glands in the skin was about 5 microns, and that 1 micron particles randomly
5 delivered to the hair follicle and stratum corneum.

Most agents may not inherently be the optimal size. However, virtually any agent may be preferentially delivered to the sebaceous glands by either synthetic microspheres, or liposomes, or albumen microspheres, or other similar "delivery devices".

10 In a preferred embodiment for treatment of acne, graphite particles having an average diameter of about one micron may be placed in delivery devices, such as microsponges, having an average diameter of about five microns. The microsponges may then be suspended in a lotion. Ultrasound may be used to drive the particles into the skin. The optimal ultrasound parameters may be
15 based on the outside particle diameter (especially if particles are uniform). Selective delivery of the particles to hair and perhaps to sweat glands may be improved.

Use of such applications could enable selective delivery of anti-acne agents, or hair dye for laser hair removal, or agents which stimulate hair growth,
20 or other hair treatments, where the encapsulation diameter was used, with or without ultrasound, to preferentially deliver, and ultrasound at different parameters or laser was used to release (not necessarily to activate or interact).

These techniques may be applied to many other agents in addition to ICN dye and graphite lotions. The term "encapsulated delivery device" is used herein
25 as a generic term which encompasses all such possible items.

Pressure may be used to impel particles (i.e., graphite, carbon, or other active agent or skin contaminant particulates) into the skin, either in the spaces between the stratum corneum, into the hair ducts and hair follicles, the sebaceous oil glands, or other structures. Air pressure or other gases or liquids

may be used to enhance delivery or increase the quantity of delivered agent. A known technique for using an air pressure device for removing skin surface is described, for example, in US Patent No. 5,037,432, which is incorporated by reference.

5 Ultrasound may be used to physically deliver hair dye and to enhance penetration into the hair shaft itself (see, for example, US Patent No. 5,817,089, incorporated herein by reference). The use of ultrasound to physically drive graphite particles down for the treatment of unwanted hair or acne appears to have been suggested in the prior art. However, the applicant is aware of no prior
10 art disclosure or suggestion of: (1) the use of ultrasound to enhance the penetration of an agent into the hair shaft itself, or into surrounding cells, or (2) the use of ultrasound to drive graphite particles into spaces between the stratum corneum to enhance the effects of a skin peel process (which physically removes a portion of the outer layers of the skin surface).

15 A known skin peel process may be improved by using ultrasound to open intercellular spaces in the outer stratum corneum layer of the skin via cavitation. Then a graphite lotion may be driven in further with the same or similar ultrasound. Fibroblast stimulation may be optimized with both topical agents that are applied afterwards (while the skin is still relatively permeable) and also with
20 additional low level laser stimulation.

 The processes described above may be used to deliver two different agents, either serially or simultaneously. The two agents may then be activated by the laser together to work synergistically, or to combine and then have an effect, or to deliver two different agents that may be activated simultaneously or
25 very closely in time.

 Two entirely different laser or light beams may be delivered substantially simultaneously through the same optics at different parameters. For example, one beam may be delivered primarily to release or to activate, and a second beam primarily to treat. Additive effects may be achieved by using two beams at

the same time. For example, a known process for skin peel and hair reduction may be optimal at 1064 nm for safety and for treating all skin colors, but other wavelengths may be better to achieve a low level laser stimulation of fibroblasts. The same laser handpiece may deliver the known process for skin peel and hair
5 reduction, and either simultaneous or synchronized sequentially in time deliver another wavelength that may be optimal to complement. In the one case it may be the best wavelength to stimulate fibroblasts. In another case it may allow selection of a hair dye (or other agent) having very strong affinity for hair and very strong absorption.

10 The presently disclosed embodiments are to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

What is claimed is:

1. A process for producing preferential damage to hair exiting mammalian skin through a hair duct, the hair growing in a hair follicle and having a hair shaft
5 and a hair bulb, the process comprising:

selecting an agent having an average diameter for enabling the agent to penetrate the hair duct, the agent comprising a material for at least one of attaching to and becoming physically incorporated into at least one of the hair shaft, the hair follicle, the hair bulb and the hair duct, the agent having an
10 electromagnetic radiation absorption characteristic for enabling the agent to absorb at least a first wavelength of electromagnetic radiation from a skin-penetrating electromagnetic radiation source,

applying the agent to the skin so that the agent penetrates the skin and at least one of attaches to and becomes physically incorporated into at least one of
15 the hair shaft, the hair follicle, the hair bulb and the hair duct, and

exposing the agent to at least a first wavelength of electromagnetic radiation, whereby the agent absorbs the first wavelength of electromagnetic radiation.

- 20 2. The process of claim 1, wherein the agent has an average diameter of about one micron.

3. The process of claim 1, comprising the step of encapsulating the agent in a microencapsulation vehicle.

25

4. The process of claim 3, wherein the microencapsulation vehicle has an average diameter of about five microns.

5. The process of claim 1, comprising the step of exposing the skin to at least one enzyme.

6. The process of claim 1, comprising the step of exposing the skin to
5 ultrasound.

ABSTRACT OF THE DISCLOSURE

A system for producing preferential damage to hair exiting mammalian skin. A agent having an average diameter for enabling the agent to penetrate the hair duct is selected. The agent is designed to attach to, or become physically incorporated into, the hair shaft, the hair follicle, the hair bulb or the hair duct. The agent has an electromagnetic radiation absorption characteristic which enables the agent to absorb a first wavelength of electromagnetic radiation from a skin-penetrating electromagnetic radiation source, such as a laser. The agent is applied to the skin so that the agent penetrates the skin and attaches to or becomes physically incorporated into the hair shaft, the hair follicle, the hair bulb or the hair duct. The agent is exposed to the first wavelength of electromagnetic radiation and absorbs the first wavelength of electromagnetic radiation.




Fig. 1




Fig. 2




Fig. 3




Fig. 4





Fig. 5



RECEIVED


DEC 20 2002

TECHNOLOGY CENTER R3700

Attorney Docket: 50958.20002.11
Inventor(s): David H. McDaniel
Title: PROCESS FOR TREATMENT
OF PSORIASIS

Date: February 15, 2001
USSN: 09/819,083

Papers enclosed: 1. Status Inquiry
2. Receipt Postcard




RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK

Prepared by: WCJ/HTC:dll
dc-318477

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on
August 7, 2002



Debbie Labriny
Debbie Labriny

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David H. McDaniel

Serial No.: 09/819,083

Filing Date: February 15, 2001

For: PROCESS FOR TREATMENT OF
PSORIASIS

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

RECEIVED

DEC 20 2002

STATUS INQUIRY

TECHNOLOGY CENTER R3700

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant respectfully inquires as to the status of the above application. The last known communication regarding this application was a Decision Granting Petition dated October 15, 2001. To date, no further communication has been received on this application.

In the event that the transmittal letter is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing Docket No. 509582000211 However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 7, 2002

Respectfully submitted,

By: 

Wayne C. Jaeschke, Jr.
Registration No. 8646

Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 887-1545
Facsimile: (202) 263-8396

50958-20002.11

09/819,083 filed Dec. 17, 2001


Called GAU 3700 703-308-0858. They said the application is in the "pre-examination process" as of 2/15/02. Call back in a month.




UNITED STATES PATENT AND TRADEMARK OFFICE

[Home](#)
[Index](#)
[Search](#)
[System Alerts](#)
[eBusiness Center](#)
[News & Notices](#)
[Contact Us](#)

PATENT APPLICATION INFORMATION RETRIEVAL



Other Links



Search results for application number: 09/819,083

Application Filing Date:	02-15-2001	Class / Sub-Class:	-/-
Issue Date of Patent:	-	Location:	PETITIONS MAIL DIVISION
Examiner Name:	-	Status:	Application Undergoing Pre Processing
Group Art Unit:	3739	Attorney Docket Number:	071340.0019 7958-2002
Earliest Publication No:	-	Patent Number:	-
Earliest Publication Date:	-	Customer Number:	25227
Confirmation Number:	5784		

[Foreign Priority](#)
[Continuity Data](#)
[Publication Review](#)

File Contents History

Number	Date	Contents Description
5	03-26-2002	Incomplete Application under Rule 53(b) - Filing Date Assign
4	03-19-2002	Application Scanned
3	10-15-2001	Petition Decision - Granted
2	06-04-2001	Petition Entered
1	02-15-2001	Initial Exam Team n

HOME | INDEX | SEARCH | SYSTEM ALERTS | BUSINESS CENTER |
NEWS&NOTICES | CONTACT US | PRIVACY STATEMENT